ROSEN, TOP RANKED GLOBAL COUNSEL, Encourages Jayud Global Logistics Ltd. Investors to Secure Counsel Before Important Deadline in Securities Class Action – JYD

ROSEN, TOP RANKED GLOBAL COUNSEL, Encourages Jayud Global Logistics Ltd. Investors to Secure Counsel Before Important Deadline in Securities Class Action – JYD GlobeNewswire December 06, 2025 NEW YORK, Dec. 06, 2025 (GLOBE NEWSWIRE) — WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Jayud Global Logistics Ltd. (NASDAQ: […]

ROSEN, TOP RANKED INVESTOR COUNSEL, Encourages Inspire Medical Systems, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – INSP

(NYSE:INSP), NEW YORK, Dec. 06, 2025 (GLOBE NEWSWIRE) — WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Inspire Medical Systems, Inc. (NYSE: INSP) between August 6, 2024 and August 4, 2025, both dates inclusive (the “Class Period”), of the important January 5, 2026 lead plaintiff deadline. SO

ROSEN, TOP RANKED INVESTOR COUNSEL, Encourages Inspire Medical Systems, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – INSP

ROSEN, TOP RANKED INVESTOR COUNSEL, Encourages Inspire Medical Systems, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – INSP GlobeNewswire December 06, 2025 NEW YORK, Dec. 06, 2025 (GLOBE NEWSWIRE) — WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Inspire Medical Systems, Inc.

Zenocutuzumab-zbco (BIZENGRI®) Shows Durable Efficacy in Patients with Treatment-Naïve NRG1+NSCLC: Updated eNRGy Trial Results Presented at IASLC-ASCO NACLC

Partner Therapeutics, Inc. (PTx), a private, fully-integrated biotechnology company, announced new data from a post hoc analysis of the Phase 2 eNRGy trial (NCT02912949) evaluating zenocutuzumab in patients with treatment-naïve non-small cell lung cancer (NSCLC) harboring a neuregulin 1 (NRG1) gene fusion. Results were presented in a late-breaking oral session at the IASLC-ASCO North America

MLTX DEADLINE NOTICE: ROSEN, A GLOBAL AND LEADING LAW FIRM, Encourages MoonLake Immunotherapeutics Investors with Losses in Excess of $100K to Secure Counsel Before Important December 15 Deadline in Securities Class Action – MLTX

New York, New York–(Newsfile Corp. – December 6, 2025) – WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of MoonLake Immunotherapeutics (NASDAQ: MLTX) between March 10, 2024 and September 29, 2025, both dates inclusive (the “Class Period”), of the important December 15, 2025 lead plaintiff deadline. SO WHAT: If

Best Place to Buy Rugs (2025): Rugs Direct Recognized for Quality, Selection and Style by Expert Consumers

Expert Consumers, an independent product review publisher has released its annual findings on the best place to buy rugs for 2025. Rugs Direct has been recognized for consistent performance across key criteria, including product quality, design variety, material selection, user guidance, and customer-facing support. The recognition follows a multi-phase review process involving qualitative assessments, catalog

BioNTech and OncoC4 Announce Clinically Meaningful Overall Survival Benefit for Selective Treg Modulator Gotistobart in Patients with Previously Treated Squamous Non-Small Cell Lung Cancer

(NASDAQ:BNTX), Selective Treg modulator gotistobart (BNT316/ONC-392) showed a reduction in the risk of death by more than half compared to standard of care chemotherapy and a manageable safety profile in the first of two stages of the global Phase 3 trial PRESERVE-003 in patients with squamous non-small cell lung cancer (“sqNSCLC”) who have progressed on

BioNTech and OncoC4 Announce Clinically Meaningful Overall Survival Benefit for Selective Treg Modulator Gotistobart in Patients with Previously Treated Squamous Non-Small Cell Lung Cancer

BioNTech and OncoC4 Announce Clinically Meaningful Overall Survival Benefit for Selective Treg Modulator Gotistobart in Patients with Previously Treated Squamous Non-Small Cell Lung Cancer GlobeNewswire December 06, 2025 Selective Treg modulator gotistobart (BNT316/ONC-392) showed a reduction in the risk of death by more than half compared to standard of care chemotherapy and a manageable safety

Geekstake Reviews Risk Signals Across Multi-Chain Networks in Response to Global Economic Uncertainty

New York, USA, Dec. 06, 2025 (GLOBE NEWSWIRE) — GeekStake today released a macro-level market update examining risk indicators across major blockchain networks as global economic uncertainty continues to influence digital-asset participation. According to Geekstake's analysis, recent fluctuations in inflation expectations, shifting liquidity cycles, and varied geopolitical pressures have contributed to heightened volatility across Bitcoin,

Geekstake Reviews Risk Signals Across Multi-Chain Networks in Response to Global Economic Uncertainty

Geekstake Reviews Risk Signals Across Multi-Chain Networks in Response to Global Economic Uncertainty GlobeNewswire December 06, 2025 New York, USA, Dec. 06, 2025 (GLOBE NEWSWIRE) — GeekStake today released a macro-level market update examining risk indicators across major blockchain networks as global economic uncertainty continues to influence digital-asset participation. According to Geekstake's analysis, recent fluctuations

Scroll to Top